Literature DB >> 35064290

Diagnostic, grading and prognostic role of a restricted miRNAs signature in primary and metastatic brain tumours. Discussion on their therapeutic perspectives.

Emiliya Nikolova1,2, Christian Georgiev3, Lili Laleva4, Milko Milev4, Toma Spiriev4, Stoycho Stoyanov4, Teodora Taseva-Mineva5, Vanyo Mitev6, Albena Todorova6,7.   

Abstract

At present, brain tumours remain one of the "hard-to-treat" malignancies with minimal improvement in patients' survival. Recently, miRNAs have been shown to correlate with oncogenesis and metastasis and have been investigated as potential biomarkers for diagnosis, prognosis and therapy prediction in different brain malignancies. The aim of the current study was to select an accurate and affordable brain tumour detection and grading approach. In the present study, we analysed the applicability of a restricted miRNA signature that could differentiate among patients with primary as well as metastatic brain tumours. Fresh tumour tissues were collected from Bulgarian patients (n = 38), including high-grade gliomas (n = 23), low-grade gliomas (n = 10) and brain metastases (n = 5) from lung cancer. Total RNAs enriched with microRNAs were isolated and differentially expressed miRNAs were analyzed by RT-qPCR using TaqMan Advanced miRNA assay. We selected a signature of miR-21, miR-10b, miR-7, miR-491 that showed good diagnostic potential in high-grade gliomas, low-grade gliomas and brain metastases compared with normal brain tissues. Our results showed that miR-10b could reliably differentiate brain metastases from high-grade gliomas, while miR-491 could distinguish low-grade from high-grade gliomas and brain metastases from low-grade gliomas. We observed that miR-21 and miR-7 correlated with disease recurrence, survival status and the Karnofsky Performance Status. The selected signature of miR-7, miR-21, miR-10b and miR-491 could be used as a highly accurate diagnostic, grading and prognostic biomarker in differentiating various types of brain tumours. Our data suggest that the 4-miRNAs signature could be further analysed for predicting treatment response and for future miRs-based targeted therapy. The ongoing studies on miRs-based targeted therapy related to our selected miRNA signature are also reviewed.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Diagnosis; High-grade glioma; Low-grade glioma; Metastases; Prognosis; miR

Mesh:

Substances:

Year:  2022        PMID: 35064290     DOI: 10.1007/s00438-021-01851-5

Source DB:  PubMed          Journal:  Mol Genet Genomics        ISSN: 1617-4623            Impact factor:   3.291


  3 in total

1.  Low Expression of miR-491-3p Is Correlated with Lymph Node Metastasis in Gastric Cancer.

Authors:  Haiou Yu; Shuang Luo
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-30       Impact factor: 2.650

2.  GlioMarker: An integrated database for knowledge exploration of diagnostic biomarkers in gliomas.

Authors:  Zihan Ran; Jingcheng Yang; Yaqing Liu; XiuWen Chen; Zijing Ma; Shaobo Wu; Yechao Huang; Yueqiang Song; Yu Gu; Shuo Zhao; Mengqi Fa; Jiangjie Lu; Qingwang Chen; Zehui Cao; Xiaofei Li; Shanyue Sun; Tao Yang
Journal:  Front Oncol       Date:  2022-08-11       Impact factor: 5.738

3.  miRNAs in Serum Exosomes for Differential Diagnosis of Brain Metastases.

Authors:  Silvia Catelan; Debora Olioso; Alessandra Santangelo; Chiara Scapoli; Anna Tamanini; Giampietro Pinna; Francesco Sala; Giuseppe Lippi; Antonio Nicolato; Giulio Cabrini; Maria Cristina Dechecchi
Journal:  Cancers (Basel)       Date:  2022-07-18       Impact factor: 6.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.